Aggressive Lymphoma Linked with JAK Inhibitor Use

Small molecular inhibitors of the Janus kinase (JAK) signaling pathway have been developed of the past several years to effectively treat a host of disorders, such as rheumatoid arthritis, Crohn’s disease, and even cancer. Yet now, new evidence from investigators at the Medical University of Vienna has emerged describing how some patients taking JAK inhibitors to treat myelofibrosis—a rare bone marrow cancer in which too many blood cells are produced—may develop aggressive lymp